Intelligence · Patents
Patents expiring in 2041
Annual patent cliff calendar for 2041 — US pharmaceutical patents by expiration date.
- Patents
- 2,000
Quick answer
2,000 indexed pharmaceutical patents have expiration dates in 2041. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11207283
Inactivators of toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria
granted -
US 11208640
Modulating human Cas9-specific host immune response
granted -
US 11208493
Internalizing human monoclonal antibodies targeting prostate and other cancer cells
granted -
US 11208479
CX43 hemichannel antibodies and methods of use
granted -
US 11208470
DNA antibody constructs and method of using same
granted -
US 11208456
Anti-KRAS-G12D T cell receptors
granted -
US 11208634
Deimmunized therapeutic compositions and methods
granted -
US 11208458
Compositions and methods for internalizing enzymes
granted -
US 11208416
Selective inhibitors of protein arginine methytransterase 5 (PRMT5)
granted -
CN 113874050
MODIFIED CYANINE DYES AND CONJUGATES THEREOF
granted -
US 11213526
Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
granted -
US 11213593
Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
granted -
US 11214621
Methods for treating chronic sinusitis with nasal polyps by administering an IL-4R antagonist
granted -
US 11213513
Compositions and methods for promoting hair growth with Mpc1 inhibitors
granted -
US 11215617
Treatment of metastatic prostate cancer
granted -
US 11214803
Modulators of YAP1 expression
granted -
US 11214802
RNAi agents for inhibiting expression of alpha-ENaC and methods of use
granted -
US 11214801
RNAi agents and compositions for inhibiting expression of apolipoprotein C-III (APOC3)
granted -
US 11214603
C3D cellular and acellular vaccines for the prevention and treatment of cancer
granted -
US 11214574
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 11214567
Small molecule inhibitors of MYC and uses thereof
granted -
US 11214595
BK channel-modulating peptides and their use
granted -
US 11214569
Prodrugs of quinuclidine ring-containing muscarinic agonists and compositions and methods thereof
granted -
US 11214565
Compound, compositions, and methods
granted -
US 11213592
Antibody-sting agonist conjugates and their use in immunotherapy
granted -
US 11213588
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
granted -
US 11213549
Compositions and method for treating primary sclerosing cholangitis and related disorders
granted -
US 11213529
Salt of substituted urea derivative and use thereof in medicine
granted -
US 11213582
Protection against recurrent genital herpes by therapeutic immunization with herpes simplex virus type 2 ribonucleotide reductase protein subunits
granted -
US 11213514
Alpha-1-adrenergic receptor agonist therapy
granted -
US 11213524
Pharmaceutical compositions for subcutaneous administration of levosimendan
granted -
US 11213497
Antibiofilm formulations
granted
Frequently asked questions
How many pharma patents expire in 2041?
2,000 published patents in our USPTO index have expiration dates falling in calendar year 2041.